跳至主要内容
临床试验/ISRCTN12693237
ISRCTN12693237已完成1 期

A phase Ib study to assess safety and tolerability and neutralising activity of CL184 in healthy volunteers

Crucell Holland BV (The Netherlands)0 个研究点目标入组 44 人开始时间: 2007年6月22日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
44

研究概览

简要总结

2008 Results article in https://pubmed.ncbi.nlm.nih.gov/18804136/ (added 01/09/2021)

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Healthy volunteers between 19 and 55 years of age
  • 2. No previous treatment with rabies vaccine
  • 3. Body Mass Index (BMI) between 18 and 28 kg/m^2

排除标准

  • 1. Pregnant women, women planning to become pregnant and breastfeeding women
  • 2. A history of or currently active clinically significant cardiac (including clinically significant abnormalities on Electrocardiogram [ECG] according to Principal Investigator [PI]), pulmonary, gastrointestinal, hepatic, renal, pancreatic, or neurological disease

研究者

发起方
Crucell Holland BV (The Netherlands)

相似试验